Table 3.
Clinical trials of cellular treatment in natural killer/T cell lymphoma
| Cellular treatment | Target | Intervention/treatment | Disease | Trial name | Number of enrolled participants | Phase | Status | Trial identifier | Dose |
|---|---|---|---|---|---|---|---|---|---|
| CAR-T cells | CD7 | CD7 CAR-T cells infusion | T-lymphoblastic Lymphoma, NK/T cell Lymphoma, Acute Lymphocytic Leukemia | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T cell Lymphoma, T-lymphoblastic Lymphoma, and Acute Lymphocytic Leukemia | 10 | Phase 1 | Recruiting | NCT04004637 | 0.5-5×106/kg |
| CD7-specific CAR gene-engineered T cells | T cell Acute Lymphoblastic Leukemia T cell Acute Lymphoblastic Lymphoma Acute Myeloid Leukemia NK Cell Lymphoma |
Multi-CAR T cell Therapy Targeting CD7-positive Malignancies | 30 | Phase 1 and phase 2 | Recruiting | NCT04033302 | NA | ||
| CD7 UCAR-T cells | CD7+ T/NK Cell Hematologic Malignancies | Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies | 30 | Early phase 1 | Recruiting | NCT04264078 | Three levels: 1×107 cells/kg, 3×107 cells/kg, 5 ×107 cells/kg | ||
| CD30 | Anti-CD30 CAR-T cells | Adult T cell Lymphoma/Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T cell Lymphoma, NK/T cell Lymphoma, Peripheral T cell LymphomaHodgkin Lymphoma | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies | 50 | Phase 1 | Recruiting | NCT04008394 | NA | |
| Anti-CD30 CAR-T cells, Cyclophosphamide, Fludarabine | Lymphoma, Large-Cell, Anaplasitc, Enteropathy-Associated T cell Lymphoma, Lymphoma, Large B-Cell, DiffuseLymphoma, Extranodal NK-T-Cell, Lymphoma, T cell, Peripheral | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | 26 | Phase 1 | Completed | NCT03049449 | 0.3x106 cells/kg (up to a maximum dose of 18x106 CAR+ T cells/kg) | ||
| Anti-CD30 CAR T cells | Lymphomas | CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) | 20 | Phase 1 and phase 2 | Unknown | NCT02274584 | NA | ||
| Anti-CD30 CAR-T cells | CD30 positive NHL subtypes (ALCL, PTCL-NOS, ENKTL, DLBCL-NOS, PMBCL) | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (CERTAIN) | 21 | Phase 1 | Recruiting | NCT04526834 | Three levels: 2 x 108 cell/m2, 4 x 108 cell/m2, 6 x 108 cell/m2 | ||
| Anti CD30 CAR-T cells | Hodgkin Lymphoma, NK/T cell Lymphoma, Peripheral T cell Lymphoma, Unspecified; Angioimmunoblastic T cell Lymphoma, Anaplastic Large Cell Lymphoma, Diffuse Large B Cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma, Gray Zone Lymphoma | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | 9 | Early phase 1 | Not yet recruiting | NCT05208853 | Three levels: 1.5×107 cells, 1.5×108 cells, 5× 108 cells | ||
| Activated/stimulated T cells and LMP1/2- or LMP2-targeted strategies | Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Leiomyosarcoma | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma (ALCI) | 74 | Phase 1 | Completed | NCT00671164 | 2 x 107 cells/m2-2 x 108 cells/m2 | ||
| EBV-CTLs | LMP1/LMP2 (EBV antigens) | Baltaleucel-T cells | EBV Positive Extranodal NK/T cell Lymphoma | Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma (CITADEL) | 15 | Phase 2 | Terminated | NCT01948180 | 2x107 cells/m2 |
| EBViNT Cells | EBV Associated Extranodal NK/T cell Lymphoma, EBV-Associated Gastric Carcinoma | A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T cell) in Patients With Treatment Failed Epstein-Barr virus (EBV)-Positive Malignancies | 72 | Phase 1 and phase 2 | Recruiting | NCT03789617 | 1.4x109 cells/100mL | ||
| Epstein-Barr virus human cytotoxic T lymphocytes (EBV-CTLs) | Extranodal NK/T cell Lymphoma | VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T cell Lymphoma Patients | 48 | Phase 2 | Recruiting | NCT03671850 | NA |
CAR-T, Chimeric antigen receptor T-cell; NHL, non-Hodgkin lymphomas; Anaplastic Large Cell Lymphoma; PTCL-NOS, peripheral T cell lymphoma not otherwise specified; ENKTL, Extranodal NK/T-cell Lymphoma; DLBCL-NOS, Diffuse Large B Cell Lymphoma not otherwise specified; PMBCL, Primary Mediastinal Large B-Cell Lymphoma; LMP1/2, Latent membrane protein 1/2.